INTRODUCTION {#s1}
============

The term "transgender" refers to a diverse population of people whose gender identities and/or expressions differ from the sex assigned to them at birth, typically via birth certificate. The variety of terms and ways of expressing gender preclude an exhaustive list of terms. Therefore, "trans feminine" refers to individuals who were assigned a male sex at birth and express their gender along a feminine spectrum---that is, as women, female, transgender women, male-to-female, and other diverse trans feminine gender identities and expressions. "Trans masculine" refers to people who were assigned female at birth and express their gender along a masculine spectrum, as men, male, transgender men, female-to-male, and other heterogeneous trans masculinities. Some transgender people do not identify within this binary of masculine and feminine. Unfortunately, at this time, there is still too little data to review among this nonbinary population; future research is needed to elucidate HIV-related risks and resiliencies in that group.

Reliable estimates of the size of the transgender population are sparse. Where they exist, data vary by location and study design. Data from gender clinics in Europe estimate that anywhere from 4.28 per 100,000^[@R1]^ to 600 per 100,000^[@R2]^ members of the population seek medical care for gender transition, and that 72%--80% of those seeking gender care identify along the trans feminine spectrum. However, recent population-based studies have found that 0.5%--0.9% of adults was identified with a gender different from their birth sex and the proportion is similar for birth-assigned males and females.^[@R3]--[@R5]^ The most recent population-based data from the United States estimate that 0.5% of the population was identified as transgender.^[@R6]^ This proportion is consistent with passport identity data from New Zealand^[@R7]^, yet much lower than the 1.2% who identified as transgender in a recent nationally representative sample of New Zealand high school students.^[@R8]^

Historically, HIV data have conflated gender with anatomy and subsumed trans feminine people under the category of men who have sex with men (MSM).^[@R9]^ Subsuming trans feminine individuals in the category of MSM is not only inaccurate, it also typically results in very small numbers of trans feminine people included in much larger samples of MSM and makes it difficult to distinguish their unique HIV vulnerabilities. Current HIV risk categories also make it difficult to identify HIV risk among trans masculine individuals. Where surveillance exists for this population, reported data have categorized trans masculine MSM under "heterosexual contact," making their risks invisible.^[@R10]^

HIV risk among transgender populations is driven by multilevel factors (Figure [1](#F1){ref-type="fig"}).^[@R11],[@R12]^ At the biological level, transgender people with anatomically male partners face a high HIV transmission probability via condomless anal sex with serodiscordant and viremic partners.^[@R13],[@R14]^ Coinfection with perigenital or perianal STIs may also potentiate the acquisition and transmission of HIV.^[@R15],[@R16]^ Hormone-related determinants of HIV risk include testosterone use among trans masculine individuals, which may cause vaginal atrophy and increase the risk of HIV acquisition during vaginal intercourse.^[@R17]^ Network level risks include a high prevalence of HIV and limited awareness of HIV status within transgender-inclusive sexual networks.^[@R18],[@R19]^ Community-level stigma and structural-level discriminatory laws also contribute to the high burden of HIV by limiting the provision and uptake of services as well as by driving transgender women, in particular to engage in sex work for economic survival and gender affirmation.^[@R20]--[@R23]^

![Multilevel drivers of HIV risk among transgender populations.](qai-72-s210-g001){#F1}

A systematic review and meta-analysis of the burden of HIV in trans feminine populations was published in 2012.^[@R24]^ In that analysis, Baral et al documented a worldwide HIV prevalence of 19% and a 49-fold increased odds of HIV infection compared with non-transgender adults of reproductive age. The review was limited to studies published between 2000 and 2011, with at least 50 participants, and laboratory-confirmed HIV-infection data. The most recent systematic review of HIV prevalence to include trans masculine individuals was published in 2008 and was limited to the United States.^[@R25]^ In that review, Herbst et al found only 5 studies among transgender men, and HIV prevalence ranged from 0% to 2%. Given the dramatic increase in research among transgender populations in recent years,^[@R26]^ an update and synthesis of HIV data among transgender populations is due.

Regardless of geographic location, transgender people exist within social contexts that stigmatize them.^[@R27]^ Stigma is a powerful social determinant of health^[@R28]^ and a key driver of HIV disparities among transgender populations.^[@R11]^ Therefore, transgender HIV data are best understood within the social context and consequences of widespread stigma. Moreover, HIV infection is only one of the multiple stigma-related health conditions that disproportionately impact transgender populations. Syndemics have been defined as "the concentration and deleterious interaction of 2 or more disease or other health conditions in a population, especially as a consequence of social inequity and the unjust exercise of power."^[@R29]^ Syndemic psychosocial health problems, such as depression, substance use or abuse, violence or victimization, and internalized transphobia, may potentiate HIV risk and contribute to poor HIV treatment outcomes for transgender populations.^[@R30]^ A recent review of the use of syndemic theory in HIV research found that most studies focused on MSM, and the most frequently studied psychosocial problems included mental health (83%), substance abuse (90%), and violence (68%). The most frequently studied outcome variables were HIV risk behaviors (73%) or HIV infection (23%).^[@R31]^ No systematic review has yet examined the data on syndemic production of HIV among transgender populations.

METHODS {#s2}
=======

PubMed (MEDLINE), EMBASE, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) were searched for English language articles. In addition, experts in HIV infection among transgender populations were contacted to request access to unpublished HIV prevalence data. Commonly used terms for transgender (including "transsexual," "cross dresser," "transvestite," and "travesti") were cross-referenced with medical subject headings (MeSH) terms for HIV. Two reviewers independently conducted title and abstract reviews on unduplicated references for relevance, with subsequent full-text review for data abstraction.

The search was limited to data published between January 1, 2012 and November 30, 2015 to avoid overlap with Baral et al\'s review.^[@R32]^ All studies with original quantitative HIV data that disaggregated transgender participants from other populations were included. Both self-reported and laboratory-tested HIV statuses and data on location of study, sampling strategies, sample size, and HIV prevalence and/or incidence were extracted. When present, data on syndemics among transgender populations were also abstracted. Where more than one manuscript reported on the same data set, the most recent publication is cited. Where a manuscript included both self-reported HIV status and HIV testing, the results of HIV tests were recorded. Where available, nonadjusted HIV-prevalence estimates were recorded for studies that used respondent-driven sampling.

RESULTS {#s3}
=======

HIV Prevalence {#s3-1}
--------------

### United States {#s3-1-1}

Twenty-one studies published between 2012 and 2015 described HIV prevalence among transgender people in the United States of which only one also measured incidence.^[@R33]^ (Table [1](#T1){ref-type="table"}.) Four studies were national, regional, or state-level in scope, whereas the rest were single city or multicity. Three cities (San Francisco and Los Angeles, CA; Boston, MA) accounted for more than half (n = 12) of study sites. One study^[@R49]^ used respondent-driven sampling, whereas the rest drew upon convenience or clinic-based samples. Eight studies included prevalence estimates for very small samples (ie, n \< 100), predominantly for trans masculine individuals. Four articles did not disaggregate prevalence data by trans feminine or trans masculine gender spectrum.^[@R34],[@R35],[@R41],[@R43]^ However, one of these articles used data from a previously published report that did disaggregate by gender spectrum.^[@R35],[@R36]^

###### 

HIV Prevalence and Incidence Among Transgender People in the United States, 2012--2015

![](qai-72-s210-g002)

Self-reported HIV prevalence in trans feminine adults^[@R13],[@R37],[@R40],[@R47],[@R48],[@R50],[@R51]^ ranged from 2.0% in a national internet-based sample^[@R16]^ to 29.9%^[@R18]^ in a sample of trans women with a history of sex work in San Francisco and Oakland, CA. Laboratory-confirmed HIV prevalence reached 35.0% and 40.1% in community samples in San Francisco^[@R49]^ and New York,^[@R33]^ respectively. Among trans feminine testing events at the US Centers for Disease Control sites nationally, 2.7% were positive.^[@R39]^ HIV prevalence among trans feminine youth was between 4.5% and 7.9% in 3 studies^[@R42],[@R45],[@R46]^ and 15.9% in 1 study.^[@R44]^

Since 2014, 5 publications^[@R38],[@R39],[@R42],[@R52],[@R53]^ have described laboratory-confirmed HIV prevalence among trans masculine people in the United States, ranging from 0.9%^[@R52]^ to 4.3%.^[@R53]^ Of trans masculine CDC testing events,^[@R39]^ 0.5% were positive.

### Global {#s3-1-2}

#### Trans Masculine {#s3-1-2-1}

Table [2](#T2){ref-type="table"} summarizes the very few data available regarding HIV prevalence among trans masculine individuals outside the United States. Four of 5 studies had very small samples (n = 14--92). Two Canadian respondent-driven sampling studies^[@R72],[@R86]^ found no prevalent known HIV infections. Among gender clinic patients in Catalonia, Spain, 2.2% of trans masculine individuals had laboratory-confirmed HIV infection.^[@R85]^ In 2 internet studies of trans masculine people who have sex with men, self-reported prevalence was 1.4% in a global sample,^[@R87]^ and 8.0% in a sample from Spanish-speaking and Portuguese-speaking countries.^[@R83]^

###### 

HIV Prevalence and Incidence Among Trans Feminine People Outside the United States, 2012--2015
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#### Trans Feminine {#s3-1-2-2}

Thirty-three studies published between 2012 and 2015 described the HIV infection burden among trans feminine individuals globally^[@R16],[@R54]--[@R83]^; 3 included incidence data.^[@R58],[@R74],[@R84]^ (Table [3](#T3){ref-type="table"}). All were from countries with male-predominant, concentrated epidemics. Seven studies used respondent-driven sampling and 1 abstract reported an unspecified probability-based sampling method. Three countries in Latin America (Peru, Brazil, and Argentina) and 3 in Asia (India, Pakistan, and Thailand) accounted for over half of reports. For Colombia, El Salvador, China, Vanuatu, Italy, and Portugal, all HIV burden data were based on samples with fewer than 100 participants. In Latin America and the Caribbean, laboratory-confirmed HIV prevalence ranged from 13.8% to 34.1%; in half of such studies, more than one-quarter of trans feminine persons were HIV-positive. Only self-reports were available from East and Southeast Asia, where data were limited by low levels of HIV testing.^[@R48],[@R56],[@R77],[@R79]^ Laboratory-confirmed HIV prevalence in India varied by sampling design, but was 18.1% in a probability sampling study.^[@R81]^ Among hijra sex workers in Pakistan, laboratory-confirmed prevalence was 6.4%--7.2% in 2 studies,^[@R71],[@R75]^ and 21.6% in a third.^[@R69]^ Laboratory-confirmed and self-reported HIV prevalence, and sampling approaches were highly variable in other countries, primarily in southern Europe.

###### 

HIV Prevalence Among Trans Masculine Persons Outside the United States, 2012--2015
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### Syndemics {#s3-2}

Eight studies were identified that examined syndemics and HIV among transgender populations^[@R23],[@R44],[@R53],[@R88]--[@R92]^ (Table [4](#T4){ref-type="table"}). Only one study was conducted outside the United States.^[@R88]^ Two studies were among trans masculine individuals^[@R23],[@R53]^; and both were conducted in Boston, MA. Half of all studies were conducted in California. One study did not specify trans feminine or trans masculine gender spectrum of transgender participants.^[@R89]^ All studies were cross-sectional and none used population-based sampling methods, limiting the ability to make causal inferences or generalize beyond the study population.

###### 

Summary of Studies Examining Syndemic Production of HIV in Trans Populations, 2012--2015
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The most common syndemic factors studied included alcohol/substance use (n = 6), mental health (n = 5), and abuse/violence (n = 4). One study measured self-reported HIV status as an outcome; 7 studies measured sexual risk behaviors, including condomless intercourse, multiple partners, and history of STIs as primary outcomes. One study among people living with HIV examined only biomedical conditions (tuberculosis, viral hepatitis, and STIs) as syndemics with HIV infection.^[@R89]^ Antitransgender stigma, discrimination, or victimization factors were included in all studies of syndemics in trans feminine individuals (n = 5). These variables were modeled both as component conditions of syndemics (n = 3) and as potential determinants of syndemic production (n = 2). Stigma was not measured in any of the studies among trans masculine individuals.

Central to syndemics theory is that harmful social factors and health conditions are *concentrated* in affected populations and *interact* to enhance deleterious consequences, such as increased HIV risk.^[@R29]^ All of the identified studies found support for the concentration of harmful social factors and/or co-occurring health conditions among transgender people and most found that these factors/conditions were associated with HIV risk. However, few studies included methods to test for associations between the factors or synergistic (interactive) effects on health. Four studies report dose--response relationships between syndemic factors and HIV-related outcomes that suggest additive, rather than synergistic effects.^[@R44],[@R88],[@R89],[@R91]^ Five studies^[@R23],[@R44],[@R88],[@R90],[@R91]^ operationalized syndemics by creating a composite index of scales to measure each included factor.

Two studies explored syndemic factors among trans masculine individuals. A small clinic sample (n = 23) of trans masculine individuals found that both alcohol use and psychosocial distress were associated with sexual risk behaviors.^[@R53]^ A larger study (n = 173) of trans masculine adults who had sex with nontransgender men found an association between the number of negative psychosocial conditions (alcohol and substance use, depression, anxiety, childhood abuse, and intimate partner violence) and increased odds of sexual risk.^[@R23]^ This study also found a significant interaction between the number of psychosocial conditions and social gender transition; however, interactions between the psychosocial conditions themselves were not examined.

The 2 studies that examined syndemics among trans feminine youth were both based in Los Angeles. Wilson et al found that an index including depression, trauma, bullying, stigma, and parental rejection was associated with both HIV risk behaviors and self-reported HIV (n = 282)^[@R91]^, and Brennan et al found associations between HIV risk and self-esteem, substance use, and victimization (n = 151).^[@R44]^

Among trans feminine adults, a San Francisco-based study developed a syndemic index of alcohol, drug use, and condomless anal intercourse and found that stigma was independently associated with this index (n = 191).^[@R90]^ However, no significant association was found between the index itself and self-reported HIV status. The study did identify significant correlations between the syndemic factors themselves. Zimmerman et al^[@R92]^ used structural equation modeling to test whether components of a syndemic of mental health problems, drug use, and alcohol use mediate the relationship between stigma and HIV risk behaviors among trans feminine people (n = 117) in Richmond and Washington, DC. This method was unique in allowing for multiple co-occurring HIV risk outcomes (eg, multiple partners, condomless sex, etc.) and multiple associated psychosocial risk factors. However, the model did not allow for correlations between the syndemic factors themselves.

Within a syndemic framework, Chu et al examined coinfection with HIV and at least one other disease (including tuberculosis, viral hepatitis, and sexually transmitted infections) among over 15,000 people living with HIV in San Francisco and found that comorbidity was more common among transgender people than nontransgender people.^[@R89]^ They also found a significant positive correlation between the number of co-occurring infections and mean viral loads. The one study from outside the United States recruited participants from 4 states in India. Chakrapani et al found that depression, alcohol, and victimization were associated with sexual risk for trans feminine participants (n = 300).^[@R88]^

DISCUSSION {#s4}
==========

These data make it clear that trans feminine populations in the United States and around the world have a remarkably high prevalence and incidence of HIV infection. The discrepancy between self-reported HIV prevalence and laboratory-confirmed HIV suggests that many trans feminine individuals remain unaware of their HIV status and thus cannot benefit from early treatment and may be at risk of onward HIV transmission. While limited, data among trans masculine populations suggest low risk relative to trans feminine populations, with the potential exception of transgender men who have sex with nontransgender men. Public health agencies should increase HIV testing in these populations^[@R39]^ to identify those who are unaware of their HIV-positive status and effectively link them to HIV care and treatment programs.

The quality and quantity of HIV data on transgender populations are improving, but remain limited. HIV burden estimates from the reviewed studies should be cautiously interpreted in light of data limitations, particularly small sample sizes and convenience sampling from HIV prevention programs, sex work venues, and other settings that are likely to generate higher-risk samples. Globally, the lack of available HIV prevalence data among transgender people in sub-Saharan Africa and Eastern Europe/Central Asia represents a priority area for future epidemiologic research. In the United States, most recent HIV data in transgender populations have come from specialized centers in Massachusetts and California serving high numbers of lesbian, gay, bisexual, and transgender individuals in metropolitan urban areas. It will be important to identify the specific HIV-related needs of transgender people in rural areas of the United States, especially in the South where prevalence of HIV infection is highest.^[@R93]^

Accurate data capture of HIV risk in transgender populations requires gender-affirmative sexual and behavioral risk assessments that assess anatomical structures in a sensitive way while being socially affirming of individual gender identities. Although condomless receptive anal sex appears the most predominant proximal risk behavior for trans feminine people globally, trans feminine people may also have condomless insertive anal sex.^[@R13],[@R42]^ Similarly, trans masculine people may have receptive vaginal sex with nontransgender male partners,^[@R15],[@R42]^ and condomless vaginal sex may be more common than condomless anal sex for this population.^[@R72]^ Additionally, the types of sex transgender people have, and levels of risk behaviors they engage in, may differ by partner type (eg, transactional sex partners, casual partners, main/primary partners).^[@R94]^

The variability in HIV prevalence estimates within and across geographic locations indicates the importance of context. In the United States, trans feminine people of color have the highest prevalence of HIV in every study that included an analysis by race. Trans feminine people of color face unique social and economic vulnerabilities created by the intersection of gender identity stigma and the systemic racism that potentiates a higher prevalence of HIV among people of color in the general US population.^[@R21],[@R93],[@R95],[@R96]^ Even within racial groups in close geographic proximity, access to care can vary widely by municipality.^[@R97]^ Similar dynamics impact racial/ethnic minorities and migrants in Europe and elsewhere, who face additional barriers to health care and social inclusion if they are undocumented.^[@R98]^ For example, data from Spain and Portugal indicate that HIV infection disproportionately impacts trans feminine sex workers who have migrated from Latin America.^[@R70],[@R73],[@R76],[@R85]^ Lower access to healthcare, increased levels of poverty and housing instabilities, treatable STIs, lower levels of health literacy, higher HIV prevalence in social networks, and higher network or community viral load are all potential explanatory factors producing and maintaining inequities in HIV infection for trans feminine people of color and migrants. The combination of high burden of HIV, systemic disadvantage, and unmet need for gender affirming services make trans feminine people of color an underserved and priority population for HIV testing, prevention, and treatment.

Existing data on syndemics suggest difficulty in successfully treating and preventing HIV infection in isolation from the other social, behavioral, and medical conditions that co-occur and interact to limit successful and sustained engagement in health care. However, research on syndemic production of HIV among transgender populations is nascent. Studies that aim to examine syndemics often do not use methods that capture both the concentration of co-occurring psychosocial conditions and their interaction to produce synergistic deleterious effects.^[@R99]^ As the importance of syndemics becomes increasingly clear, more sophisticated analytic methods are needed.^[@R31],[@R99]^ This includes examining the developmental trajectories of syndemics, such as timing, onset, and antecedents, to inform early prevention efforts and identifying appropriate multimodal interventions that address syndemics and the barriers they present to effective engagement in HIV prevention and treatment programs, including initiation of and adherence to oral pre-exposure prophylaxis (PrEP) and antiretroviral medications (ART) for those living with HIV.^[@R100],[@R101]^

ART and PrEP have emerged as powerful tools in the HIV response. However, unless HIV services are acceptable and accessible to transgender people, coverage and ultimate effectiveness of these interventions will be limited. Emerging data suggest that HIV services are more acceptable to transgender people when they are destigmatizing and include access to gender-affirming care.^[@R102],[@R103]^ Although there are specialized centers in a few urban settings that provide primary care and HIV wrap-around services, the clearly identified and urgent need for transgender-competent HIV services has largely gone unmet globally. Programs designed for MSM are inappropriate for trans feminine populations^[@R104]^ and are likely to be unacceptable to individuals who do not identify as men.^[@R105]^ At the same time, MSM programs may be unwelcoming to trans masculine individuals who have sex with men who may desire and benefit from MSM services.^[@R15],[@R87]^

Although many of the syndemic conditions described for transgender populations are also well-known determinants of health for other groups,^[@R29]^ transgender populations face additional challenges of gender-related stigma, unmet gender affirmation needs, and inadequately trained health care providers.^[@R106]^ In combination, these factors form significant challenges to engagement in HIV prevention and treatment. The enormous burden of HIV, especially among trans feminine individuals, suggest a growing epidemic that requires us to address these challenges to engage transgender people and meet global objectives for HIV prevention and care. Future research should prioritize filling critical gaps in HIV epidemiology among transgender people in sub-Saharan Africa and Eastern Europe and rural areas globally. Studies are needed to clarify how stigma shapes syndemic factors to produce HIV and other deleterious effects on transgender health and ultimately to understand how best to implement acceptable, accessible, and effective HIV interventions for transgender people.
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